μ- and δ-Opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease

Experimental Neurology

Volumn 171, Issue 1, 2001, Pages 139-146

  Henry, Brian ^a   Fox, Susan H ^b   Crossman, Alan R ^b   Brotchie, Jonathan M ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b Williams House   (United Kingdom)

Author keywords

1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine lesioned marmoset; Dyskinesia; Opioid peptides; Opioid receptor antagonists; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CYPRODIME; DELTA OPIATE RECEPTOR ANTAGONIST; LEVODOPA; MU OPIATE RECEPTOR ANTAGONIST; NALTRINDOLE; NORBINALTORPHIMINE; OPIATE PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SELECTIVITY; DYSKINESIA; FEMALE; LONG TERM CARE; MALE; MARMOSET; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 0034851915     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.2001.7727     Document Type: Article

References (69)

1. Reduction of dyskinesia and induction of akinesia induced by morphine in two parkinsonian patients with severe sciatica
2. Dymorphin A processing enzyme: Tissue distribution, isolation, and characterization
3. Stimulation of dopamine synthesis in caudate nucleus by intrastriatal enkephalins and antagonism by naloxone
4. Naloxone may be beneficial in the treatment of tardive dyskinesia
5. Opioid peptide precursor expression in animal models of dystonia secondary to dopamine-replacement therapy in Parkinson's disease
6. Quantitative assessment of dyskinesias in subhuman primates
7. Review of naltrexone, a long-acting opiate antagonist
8. A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: Implications for future strategies in treatment
9. Evidence for a long Leuenkephalin striopallidal pathway in rat brain
10. Neostriatal enkephalin-immunoreactive neurones project to the globus pallidus
11. International Union of Pharmacology. XII. Classification of opioid receptors
12. Enhancement of the behavioral response to apomorphine administration following repeated treatment in the 6-hydroxydopamine-lesioned rat is temporally correlated with a rise in striatal preproenkephalin-B, but not preproenkephalin-A, gene expression
13. Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes
14. Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism
15. Distribution of striatonigral and striatopallidal peptidergic neurons in both patch and matrix compartments: An in situ hybridization histochemistry and fluorescent retrograde tracing study
16. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striato-pallidal neurons
17. The neostriatal mosaic: Multiple levels of compartmental organization
18. Utility of an objective dyskinesia rating scale for Parkinson's disease: Inter- and intrarater reliability assessment
19. Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys
20. Correlation between Met-enkephalin and substance P immunoreactivity in the primate globus pallidus
21. Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease
22. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease
23. The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease
24. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat
25. Modulation of glutamate release by a kappa-opioid receptor agonist in rodent and primate striatum
26. Modulation of glutamate transmission in the basal ganglia by enadoline, a selective kappa-opioid receptor agonist, in the marmoset and rat
27. A novel therapeutic approach to the symptomatic treatment of Parkinson's disease based on activation of delta opioid receptors
28. Problems with current pharmacologic treatment of Parkinson's disease
29. Differential effects of selective mu-, kappa- and delta-opioid antagonists on electroshock seizure threshold in mice
30. G-protein-coupled receptor heterodimerization modulates receptor function
31. Interactions between D-ala-met-enkephalin, A10 dopaminergic neurones, and spontaneous behaviour in the rat
32. A controlled trial of propoxyphene and naltrexone in patients with Tourette's syndrome
33. Comparison of therapeutic effects of levodopa, levodopa and selegiline and bromocriptine in patients with early, mild Parkinson's disease: Three year interim report
34. Dopamine receptor gene expression by enkephalin neurons in rat forebrain
35. High-dose naloxone in tardive dyskinesia
36. The binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties
37. Selectivity profile of norbinaltorphimine and ICI-197,067 in guinea pig brain
38. On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus
39. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology
40. 35S]GTPgammaS binding assays
41. Activity of pallidal neurons in the monkey during dyskinesia induced by injection of bicuculline in the external pallidum
42. The role of the subthalamic nucleus in experimental chorea. Evidence from 2-deoxyglucose metabolic mapping and horseradish peroxidase tracing studies
43. A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia
44. Reversal of parkinsonian symptoms by intrastriatal and systemic manipulation of excitatory amino acid and dopamine transmission in the bilateral 6-OHDA-lesioned marmoset
45. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: Comparison with L-DOPA therapy
46. Antinociceptive and behavioral effects of synthetic deltorphin analogs
47. A kappa opioid antagonist blocks sensitization in a rodent model of Parkinson's disease
48. Levodopa-induced dyskinesia: Review, observations, and speculations
49. Thalamotomy for the alleviation of levodopa-induced dyskinesia: Experimental studies in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated parkinsonian monkey
50. Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesia
51. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix jacchus)
52. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias
53. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease
54. Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia
55. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa
56. Differential metabolism of dynorphins in substantia nigra, striatum, and hippocampus
57. Naloxone treatment of L-dopa-induced dyskinesias in Parkinson's disease
58. Differential effects of delta- and mu-opioid receptor antagonists on the amphetamine-induced increase in extracellular dopamine in striatum and nucleus accumbens
59. Synthesis and biological evaluation of 14-alkoxymorphinans. 2. (-)-N-(cyclopropylmethyl)-4,14-dimethoxymorphinan-6-one, a selective mu opioid receptor antagonist
60. Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias
61. Selective kappa antagonist properties of nor-binaltorphimine in the rat MES seizure model
62. Effect of naloxone on the "on-off" syndrome in patients receiving long-term levodopa therapy
63. Dose-related effects of continuous levodopa infusion in rats with unilateral lesions of the substantia nigra
64. Morphine and naltrexone modulate D2 but not D1 receptor induced motor behaviour in MPTP-lesioned monkeys
65. Opioid antagonist profile of SC nor-binaltorphimine in the formalin paw assay
66. Fentanyl increases dopamine release in rat nucleus accumbens: Involvement of mesolimbic mu- and delta-2-opioid receptors
67. Effect of morphine on dynorphin B and GABA release in the basal ganglia of rats
68. A potent and selective endogenous agonist for the mu-opiate receptor